Camber Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Camber Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,327,500	Closed	-$7.43M	–	39
2016 Q3	$7.43M	Hold	1,327,500	–	–	0.33%	31
2016 Q2	$8.5M	Hold	1,327,500	–	–	0.41%	37
2016 Q1	$11.2M	Hold	1,327,500	–	–	0.65%	34
2015 Q4	$13.5M	Buy	1,327,500 +600,042	+82%	+$6.1M	0.88%	28
2015 Q3	$8.58M	Hold	727,458	–	–	0.74%	31
2015 Q2	$14.2M	Buy	+727,458	New	+$15.1M	0.97%	29
2015 Q1	–	Sell	-200,000	Closed	-$3.92M	–	30
2014 Q4	$3.68M	Hold	200,000	–	–	0.24%	39
2014 Q3	$4.84M	Hold	200,000	–	–	0.45%	35
2014 Q2	$7.3M	Hold	200,000	–	–	0.48%	35
2014 Q1	$9.16M	Hold	200,000	–	–	0.72%	32
2013 Q4	$7.78M	Buy	200,000 +21,000	+12%	+$884K	0.69%	29
2013 Q3	$8.11M	Buy	179,000 +29,000	+19%	+$1.49M	0.85%	28
2013 Q2	$7.37M	Buy	+150,000	New	+$7.96M	0.76%	35

Other funds holding PLX

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Camber Capital Management's PLX Position: Q4 2016 in Review

Camber Capital Management sold out of Protalix BioTherapeutics (PLX) in Q4 2016, closing a stake of 1,327,500 shares — an estimated $7.43M sold.

Camber Capital Management first reported a position in PLX in Q2 2013 and held it in 13 quarters. The position peaked at $14.2M in Q2 2015. 33 funds tracked by Wall St. Rank hold PLX as of Q4 2016.

Camber Capital Management reported no remaining Protalix BioTherapeutics position as of Q4 2016 after selling out during the quarter.
Camber Capital Management sold 1,327,500 Protalix BioTherapeutics shares in Q4 2016, an estimated $7.43M.
Camber Capital Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 13 quarters.
Camber Capital Management's Protalix BioTherapeutics position peaked at $14.2M in Q2 2015.
33 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2016.

Based on Camber Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.